Pharmaceuticals

Addressing unmet needs with LP-284 for relapsed/refractory lymphoma and solid tumors

bexib
By bexib 0 Min Read

In this Pharmaceutical Executive Video Interview, Panna Sharma, CEO of Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing and emerging therapies for relapsed/refractory lymphoma and solid tumors. I will explain how it is compatible.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Closet Full of Treasures? Here’s How to Sell Vintage Clothing (2024)
Next Article 2024 RealAgristudies Hockey Playoff Survey Results – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Selfridges ringing in the new year on the roof of San Carlo’s Alto
Hospitality & Tourism
Season 2024: Exceeding expectations at Borghese Contemporary Hotel
Hospitality & Tourism
JPMorgan and Bank of America respond to CFPB lawsuit
Banking
Zell says CFPB lawsuit against big banks is ‘regulatory overreach’
Banking